Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Promising new radiation therapy targets Hard-to-Treat prostate cancer

NCT ID NCT05603559

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 27 times

Summary

This early-phase study tests a new radioactive drug (177Lu-P17-087/088) in 30 men with advanced prostate cancer that has spread and no longer responds to hormone therapy. The drug seeks out cancer cells and delivers radiation directly to them. The study first checks safety and how much radiation reaches tumors and healthy organs, then tests higher doses to find the best amount for treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC CASTRATION RESISTANT PROSTATE CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Peking Union Medical College Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100730, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.